Opus Genetics (IRD) Stock: Buy, Sell, or Hold?
IRD - Opus Genetics, Inc. Common Stock
$4.58
0.07 (1.55%)
â˛
5d:
-3.78%
30d:
+2.92%
90d:
+12.53%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When IRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IRD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IRD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IRD is currently trading at $4.58, which is considered fair relative to its 30-day fair value range of $4.09 to $5.51.
Technical Outlook: Technically, IRD is in a uptrend. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IRD scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.00 (+183.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRD is in a uptrend. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IRD scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.00 (+183.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.09 -
$5.51
Company Quality Score
40/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: Trading 183.8% below Wall St target ($13.00)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.09 -
$5.51
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.45
Resistance Level
$5.55
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.41
Wall Street Target
$13.00
(+183.8%)
Revenue Growth (YoY)
-73.8%
Share & Embed Analysis
Last updated: October 04, 2026 11:00 AM ET
Data refreshes hourly during market hours. Next update: 12:00 PM
Data refreshes hourly during market hours. Next update: 12:00 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 76 BUY |
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
27 analysts |
$92 | 46 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$128 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
19 analysts |
$18 | 52 HOLD |